Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe-Reference-Cited by-同舟云学术

Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe

Published:2022-10-26 Issue: Volume: Page:1-9
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Damjanov Nemanja¹,Kirvalidze Nana²,Kurashvili Nana³,Berti Fausto⁴,Steiger Matjaz⁴,Sobierska Joanna⁴,Guenzi Eric⁵,Otto Hendrik⁶,Sattar Abid⁷,Haliduola Halimu N.⁶,Edwald Elin⁸,Stroissnig Heimo⁶

Affiliation:

1. School of Medicine, University of Belgrade, Belgrade, Serbia

2. Department of Traumatology and Orthopedics, Georgian Dutch Hospital LLC, Tbilisi, Georgia

3. Traumatology, Aleksandre Aladashvili Clinic LLC, Tbilisi, Georgia

4. Clinical and Medical Affairs, Alvotech Swiss, Zürich, Switzerland

5. Development and Project Management, UGA Biopharma GmbH, Hennigsdorf, Germany

6. Clinical and Medical Affairs, Alvotech Germany GmbH, Jülich, Germany

7. Clinical and Medical Affairs, Alvotech UK Ltd, London, UK

8. Combination Products & Devices, Alvotech Iceland, Reykjavik, Iceland

Funder

Alvotech Swiss AG

Publisher